Limits...
Detection of pancreatic cancer biomarkers using mass spectrometry.

Kim K, Ahn S, Lim J, Yoo BC, Hwang JH, Jang W - Cancer Inform (2015)

Bottom Line: We performed preprocessing, and various classification methods with imputation were used to replace the missing values.By using various classification methods, we identified the commonly splitting protein peaks as m/z 1,465, 1,206, and 1,020.In the follow-up study, in which we assessed biomarkers in pancreatic cancer patients with diabetes after surgical resection, we found that the intensities of m/z at 1,465, 1,206, and 1,020 became comparable with those of diabetes-only patients.

View Article: PubMed Central - PubMed

Affiliation: Department of Statistics, Seoul National University, Seoul, Republic of Korea.

ABSTRACT

Background: Pancreatic cancer is the fourth leading cause of cancer-related deaths. Therefore, in order to improve survival rates, the development of biomarkers for early diagnosis is crucial. Recently, diabetes has been associated with an increased risk of pancreatic cancer. The aims of this study were to search for novel serum biomarkers that could be used for early diagnosis of pancreatic cancer and to identify whether diabetes was a risk factor for this disease.

Methods: Blood samples were collected from 25 patients with diabetes (control) and 93 patients with pancreatic cancer (including 53 patients with diabetes), and analyzed using matrix-assisted laser desorption/ionization-time of flight mass spectrometry (MALDI-TOF/MS). We performed preprocessing, and various classification methods with imputation were used to replace the missing values. To validate the selection of biomarkers identified in pancreatic cancer patients, we measured biomarker intensity in pancreatic cancer patients with diabetes following surgical resection and compared our results with those from control (diabetes-only) patients.

Results: By using various classification methods, we identified the commonly splitting protein peaks as m/z 1,465, 1,206, and 1,020. In the follow-up study, in which we assessed biomarkers in pancreatic cancer patients with diabetes after surgical resection, we found that the intensities of m/z at 1,465, 1,206, and 1,020 became comparable with those of diabetes-only patients.

No MeSH data available.


Related in: MedlinePlus

Intensities of biomarkers between control and case.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4285963&req=5

f6-cin-suppl.7-2014-045: Intensities of biomarkers between control and case.

Mentions: Because bagging and random forest with PPC outperformed other methods when handling missing values (Table 1), we primarily focused on the classification results obtained using these methods. Accordingly, we found that the following were common candidates for biomarkers: m/z 175.0852, 287.0996, 402.1181, 1,020.5152, 1,206.5410, 1,207.5488, 1,208.5621, 1,465.6118, 1,466.6155, 1,467.5927, and 1,468.6177. To validate the significance of these candidates, we plotted the raw spectra for the given m/z values for pancreatic cancer patients with diabetes and patients with diabetes only. Differences in intensities were observed at m/z 1,465 1,468, 1,206 1,208, and 1,020. Figure 6 shows the difference of intensities at m/z 1,465 and 1,206.


Detection of pancreatic cancer biomarkers using mass spectrometry.

Kim K, Ahn S, Lim J, Yoo BC, Hwang JH, Jang W - Cancer Inform (2015)

Intensities of biomarkers between control and case.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4285963&req=5

f6-cin-suppl.7-2014-045: Intensities of biomarkers between control and case.
Mentions: Because bagging and random forest with PPC outperformed other methods when handling missing values (Table 1), we primarily focused on the classification results obtained using these methods. Accordingly, we found that the following were common candidates for biomarkers: m/z 175.0852, 287.0996, 402.1181, 1,020.5152, 1,206.5410, 1,207.5488, 1,208.5621, 1,465.6118, 1,466.6155, 1,467.5927, and 1,468.6177. To validate the significance of these candidates, we plotted the raw spectra for the given m/z values for pancreatic cancer patients with diabetes and patients with diabetes only. Differences in intensities were observed at m/z 1,465 1,468, 1,206 1,208, and 1,020. Figure 6 shows the difference of intensities at m/z 1,465 and 1,206.

Bottom Line: We performed preprocessing, and various classification methods with imputation were used to replace the missing values.By using various classification methods, we identified the commonly splitting protein peaks as m/z 1,465, 1,206, and 1,020.In the follow-up study, in which we assessed biomarkers in pancreatic cancer patients with diabetes after surgical resection, we found that the intensities of m/z at 1,465, 1,206, and 1,020 became comparable with those of diabetes-only patients.

View Article: PubMed Central - PubMed

Affiliation: Department of Statistics, Seoul National University, Seoul, Republic of Korea.

ABSTRACT

Background: Pancreatic cancer is the fourth leading cause of cancer-related deaths. Therefore, in order to improve survival rates, the development of biomarkers for early diagnosis is crucial. Recently, diabetes has been associated with an increased risk of pancreatic cancer. The aims of this study were to search for novel serum biomarkers that could be used for early diagnosis of pancreatic cancer and to identify whether diabetes was a risk factor for this disease.

Methods: Blood samples were collected from 25 patients with diabetes (control) and 93 patients with pancreatic cancer (including 53 patients with diabetes), and analyzed using matrix-assisted laser desorption/ionization-time of flight mass spectrometry (MALDI-TOF/MS). We performed preprocessing, and various classification methods with imputation were used to replace the missing values. To validate the selection of biomarkers identified in pancreatic cancer patients, we measured biomarker intensity in pancreatic cancer patients with diabetes following surgical resection and compared our results with those from control (diabetes-only) patients.

Results: By using various classification methods, we identified the commonly splitting protein peaks as m/z 1,465, 1,206, and 1,020. In the follow-up study, in which we assessed biomarkers in pancreatic cancer patients with diabetes after surgical resection, we found that the intensities of m/z at 1,465, 1,206, and 1,020 became comparable with those of diabetes-only patients.

No MeSH data available.


Related in: MedlinePlus